Sight Sciences Files 8-K Report

TL;DR

Sight Sciences filed an 8-K today, check for updates.

AI Summary

On October 3, 2024, Sight Sciences, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." Specific details regarding the nature of these events, any associated financial implications, or significant announcements are not elaborated upon in the provided text.

Why It Matters

This filing signals that Sight Sciences, Inc. has made a regulatory disclosure. Investors and interested parties should review the full filing for details on any material events that could impact the company's operations or stock.

Risk Assessment

Risk Level: low — The filing itself is a routine disclosure and does not contain inherently risky information, but the lack of detail requires further investigation.

Key Players & Entities

• Sight Sciences, Inc. (company) — Registrant
• October 3, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 4040 Campbell Avenue Suite 100 (address) — Principal Executive Offices
• Menlo Park, California (location) — Principal Executive Offices Location
• 94025 (zip_code) — Principal Executive Offices Zip Code
• 877 266-1144 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share SGHT Nasdaq Glo

Filing Documents

• sght-20241003.htm (8-K) — 51KB
• 0000950170-24-112038.txt ( ) — 179KB
• sght-20241003.xsd (EX-101.SCH) — 32KB
• sght-20241003_htm.xml (XML) — 5KB

01. Other Events

Item 8.01. Other Events On October 3, 2024, four Medicare Administrative Contractors ("MACs"), Palmetto GBA, CGS Administrators, National Government Services, and WPS Government Health Administrators, each individually published final local coverage determinations and related final local coverage articles (collectively, the "Final LCDs") regarding Micro-Invasive Glaucoma Surgery ("MIGS"). The Final LCDs, which are substantially similar to the proposed local coverage determinations published by each MAC in May 2024, confirm Medicare coverage for phacoemulsification / intraocular lens placement procedures performed with a single MIGS procedure. A "MIGS" procedure includes canaloplasty in combination with trabeculotomy ab interno, which is a procedural description associated with the Company's OMNI Surgical System ("OMNI"), and goniotomy, which is a procedural description associated with the Company's SION Surgical Instrument ("SION") technology. Accordingly, Medicare coverage for canaloplasty in combination with trabeculotomy ab interno procedures and goniotomy procedures will continue in the states covered by these MACs. The anticipated effective date of the Final LCDs is November 17, 2024. The Final LCDs adopt coverage limitations or non-coverage policies for MIGS procedures as first-line treatments for mild-to-moderate glaucoma, for surgical MIGS procedures (such as canaloplasty or goniotomy), when performed at the same time of service in the same patient eye as an aqueous shunt procedure, and for phacoemulsification / intraocular lens placement, when performed with a combination of MIGS procedures (e.g., cataract, stent, and either canaloplasty or goniotomy) at the same time of service in the same eye. The Company plans to continue to engage with each MAC, the Centers for Medicare and Medicaid Services, and the clinical societies in continued support of procedures performed with OMNI and SION. Cautionary Note Regarding Forward-Looking Statements This Cur

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sight Sciences, Inc. Date: October 3, 2024 By: /s/ Alison Bauerlein Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR